Tbf the way casp has been running the deeps I’d be happy if they sold them to Exxon for a good few billion. I’d take that all day long. Make it someone else’s headache and liquid cash right in the bank
Demerge a part of the company to run independently under the same parent company. The RNS initially reads like you suggested from the title but as you read the detail it possibly suggests that they are looking to sell it off.
It’s like casp demerging the shallows from the main casp portfolio. 1. It’ll make it easier to run seperately 2. If Exxon comes knocking on the door you can present the portfolio much easier of the specific value opposed to the entire company.
Allow Shareholders to benefit from both Tiziana's rapidly developing drug portfolio and the standalone value of StemPrintER as it progresses through its own development milestones and the path to commercialization and allow shareholders to receive the maximum potential value from StemPrintER as a standalone entity.
To me this suggests that they have been approached for potential buyout and have been legally advised to create a new arm under the TILS umbrella. It will enable a sale of the arm much easier opposed to splitting assets at the time of sale.
The 81p trade may have been a stop loss triggered. Happened to me before years ago, stop loss triggered 50% lower than the market value and had to buy back in @ 50% premium with a significantly smaller stake.
Bottom line don’t set a stop loss cos you’ll rarely win
RE: All other companies seem to have progessed18 May 2020 09:31
Sam, since it was announced that Roche had a CE 100% accurate antibody test and was in the public eye with government discussions associated with it, I lost faith in ODX being the market expected sole provider for antibody tests in the uk.
Since that announcement it’s just been bumbling around the 50p mark.
I’m not expecting anything significant there, so i offloaded everything and popped it all in here.